Form 8-K

8-K — NEUROONE MEDICAL TECHNOLOGIES Corp

Accession: 0001213900-26-049748

Filed: 2026-04-30

Period: 2026-04-24

CIK: 0001500198

SIC: 3841 (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS)

Item: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Item: Financial Statements and Exhibits

Documents

8-K — ea0288229-8k_neuroone.htm (Primary)

EX-10.1 — TRANSITION AND RELEASE AGREEMENT, BY AND BETWEEN THE COMPANY AND RONALD MCCLURG, DATED APRIL 28, 2026 (ea028822901ex10-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0288229-8k_neuroone.htm · Sequence: 1

false

0001500198

2026-04-24

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date

of Report (Date of Earliest Event Reported): April 24, 2026

NeuroOne

Medical Technologies Corporation

(Exact

name of registrant as specified in its charter)

Delaware

001-40439

27-0863354

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

7599

Anagram Dr., Eden Prairie, MN 55344

(Address

of principal executive offices and zip code)

952-426-1383

(Registrant’s

telephone number including area code)

(Registrant’s

former name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐ Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common Stock, par value

$0.001 per share

NMTC

The Nasdaq Stock Market

LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

Growth Company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

of Certain Officers.

April 24, 2026, Ronald McClurg notified NeuroOne Medical Technologies Corporation (the “Company”) of his intention to retire

as the Company’s Chief Financial Officer. The effective date of Mr. McClurg’s retirement as Chief Financial Officer will

be June 30, 2026. Following his retirement as an officer, Mr. McClurg will remain employed by the Company as a Senior Advisor, to ensure

a smooth transition of duties, until December 31, 2026 (the “Retirement Date”).

connection with Mr. McClurg’s retirement, the Board announced that Christopher Volker, the Company’s Chief Operating Officer,

will succeed Mr. McClurg as the Company’s Chief Financial Officer effective as of July 1, 2026. Mr. Volker has extensive experience

in the medtech industry, including senior leadership roles at Abbott, Cardiovascular Systems, Inc. (“CSI”), and St. Jude

Medical. At CSI, he served as Vice President & General Manager of International and had direct responsibility for international P&L

and commercial expansion, including sales, training & education, marketing, business development and program management. Prior to

CSI, Mr. Volker held executive leadership roles at St. Jude Medical, including senior roles in corporate finance where he reported directly

to St. Jude Medical’s Chief Financial Officer.

began his career in healthcare and technology investment banking, where he developed expertise in financial analysis, mergers and acquisitions,

strategic planning, growth equity investments and financings. Mr. Volker earned a Bachelor of Arts degree from St. John’s University

and a Master of Business Administration in Finance from the Wharton School at the University of Pennsylvania. Mr. Volker holds the Chartered

Financial Analyst® designation.

Mr.

Volker’s base salary will be increased to $350,000 in connection with his appointment as Chief Financial Officer, but the other

compensatory and material terms of Mr. Volker’s employment with the Company will remain unchanged.

connection with Mr. McClurg’s anticipated retirement, he and the Company entered into a Transition and Release Agreement, dated

as of April 28, 2026 (the “Transition Agreement”), pursuant to which Mr. McClurg will continue to receive his current salary

and employment benefits until the Retirement Date, at which time his employment with the Company will cease. In exchange for the payments

made under the Transition Agreement, Mr. McClurg provides a general release of claims, and agrees to customary restrictive covenants.

The

foregoing description of the Transition Agreement is qualified in its entirety by reference to the text of the Transition Agreement.

The form of the Transition Agreement is attached as Exhibit 10.1 hereto and incorporated herein by reference.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

No.

Description

10.1

Transition and Release Agreement, by and between the Company and Ronald McClurg, dated April 28, 2026

104

Cover Page Interactive Data File (embedded with Inline

XBRL document).

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

NEUROONE MEDICAL TECHNOLOGIES CORPORATION

Dated: April 30, 2026

By:

/s/ David Rosa

David Rosa

Chief Executive Officer

EX-10.1 — TRANSITION AND RELEASE AGREEMENT, BY AND BETWEEN THE COMPANY AND RONALD MCCLURG, DATED APRIL 28, 2026

EX-10.1

Filename: ea028822901ex10-1.htm · Sequence: 2

Exhibit 10.1

TRANSITION

AND Release Agreement

THIS

TRANSITION AND RELEASE AGREEMENT (this “Agreement”) is made as of April 28, 2026 by and between NeuroOne

Medical Technologies Corporation, a Delaware corporation (the “Company”), and Ron

McClurg (“Employee”). Capitalized terms used but not defined in this Agreement will have the meanings

ascribed to them in the Offer Letter between Employee and the Company dated January 1, 2021, as amended (the “Offer Letter”).

Recitals

Whereas,

Employee has been employed as the Chief Financial Officer of the Company since January 2021; and

Whereas,

the Company and Employee (collectively, the “Parties” and each, without distinction, a “Party”)

have mutually agreed to terminate Employee’s existing employment relationship with the Company on the terms and conditions set

forth in this Agreement.

Agreement

Now,

therefore, in consideration of the foregoing

premises and for other good and valuable consideration, the receipt and sufficiency of which are hereby expressly acknowledged, the Parties,

intending to be legally bound, hereby agree as follows:

Article

EMPLOYMENT TRANSITION

1.1 Separation

of Employment. Employee’s employment with the Company will be ending on December 31, 2026, provided that Employee may

accelerate this date for any reason and the Company may accelerate this date because of a Termination for Cause (such final date, the

“Separation Date”). To the extent it has not done so already, the Company will pay Employee’s compensation

for hours worked through the Separation Date, as well as payment for his accrued but unused vacation. The Company will reimburse Employee

for Employee’s outstanding documented business expenses remaining on the Company’s books as of the Separation Date, which

were properly reviewed and approved according to the Company’s policies in effect on the Separation Date. Employee is entitled

to the above payments regardless of whether Employee signs this Agreement and regardless of whether this Agreement becomes effective

in accordance with Section 2.2. All of Employee’s benefits through the Company will end on the Separation Date.

1.2 Transition

Period. From July 1, 2026 through the Separation Date (the “Transition Period”), Employee’s

role will be changed from Chief Financial Officer to Special Advisor, and Employee resigns his appointment as an officer of the Company

as of the commencement of the Transition Period. As Special Advisor, Employee will provide transitional support to his successor, as

well as provide services commensurate with his position as assigned by the Company. During the Transition Period: (a) Employee will continue

to receive his current annual salary and benefits; (b) he will be eligible for reimbursement of business expenses in accordance with

Company policy; and (c) he will remain eligible for a Performance Bonus with respect to the fiscal year ending on September 30, 2026,

subject to his continued employment through that date.

1.3 Consideration.

Provided that (a) the Company has not accelerated the Separation Date because of a Termination for Cause, (b) Employee executes

and delivers this Agreement (without revoking same), (c) Employee executes and delivers the Signature to Update Release Provision

appearing after the signature page (without revoking same) (the “Update Provision”) on or within seven (7)

days after the Separation Date, and (d) Employee remains in compliance with his obligations under this Agreement, then the Company agrees

to engage Employee to provide consulting services, and Employee agrees to provide consulting services, pursuant to the terms and conditions

of the consulting agreement attached hereto as Exhibit A (the “Consulting

Agreement”), with the term of the Consulting Agreement commencing as of the Separation Date. The Company acknowledges and

agrees that Employee’s performance of services pursuant to the terms and conditions of the Consulting Agreement will constitute

“Continuous Services” for the purposes of the vesting provisions of Employee’s stock options and restricted stock units.

1.4 Conflict

with Other Agreements. In the event of any conflict of the provisions between this Agreement and the Offer Letter, the provisions

set forth in this Agreement shall control, except (a) as otherwise set forth herein, and (b) the severance opportunity relating to a

potential Change in Control, as set forth in the First Amendment to the Offer Letter dated September 9, 2024 shall remain in effect through

the Separation Date. Employee agrees to strictly comply with Employee’s continuing obligations under that certain Employee Proprietary

Information, Inventions Assignment and Non-Competition Agreement entered into by and between the Company and Employee dated January 1,

2021 (the “Inventions Assignment Agreement”), the terms and conditions of which shall survive the execution

of this Agreement. In the event of any conflict of the provisions between this Agreement and the Inventions Assignment Agreement, the

terms and condition of the Inventions Assignment Agreement shall control. Employee hereby confirms to the Company that Exhibit 1

to the Inventions Assignment Agreement contains a complete list of all Inventions (as defined in the Inventions Assignment Agreement)

or improvements to which Employee claims ownership and desires to remove from the operation of the Inventions Assignment Agreement.

1.5 Acknowledgement.

Except as provided in this Article 1, the Parties acknowledge and agree that Employee shall not, after the Separation Date, be

eligible for any additional payment by the Company of any bonus, salary, vacation pay, retirement pension, severance pay, back pay, or

other remuneration or compensation of any kind in respect of employment by the Company or its affiliates.

1.6 Statement

Regarding Resignation; SEC Matters. Employee acknowledges that the Company may be required to file a copy of this Agreement

as an exhibit to a Form 8-K, Form 10-K or Form 10-Q filed with the SEC (the “Exchange Act Reports”). Employee

agrees that the Exchange Act Reports may contain a statement summarizing the terms and conditions of this Agreement and the fact that

Employee’s employment with the Company terminated as of the Separation Date (the “Exchange Act Statement”).

Employee will cooperate with the Company in providing information with respect to all reports required to be filed by the Company with

the SEC as they relate to required information with respect to Employee. Further, following the Separation Date, Employee will remain

in compliance with the terms of the Company’s insider trading policy with respect to purchases and sales of the Company’s

securities.

1.7 Company

Securities. As of the date hereof, Employee is the current holder of the following stock options and unvested RSUs issued

by the Company to Employee (the Equity Awards”):

Option / RSU

Grant Date

Plan Awarded

Under

Exercise Price

# of Shares Subject to the

Option / RSU

Option

January 1, 2021

2017 Plan

$ 28.26

10,000

Option

January 27, 2021

2017 Plan

$ 35.82

7,778

Option

April 21, 2023

2017 Plan

$ 9.54

2,084

Option

November 9, 2023

2017 Plan

$ 7.50

14,881

Option

April 17, 2025

2025 Plan

$ 3.48

41,667

RSU

February 18, 2024

2017 Plan

N/A

9,476

Following

the Separation Date, the Equity Awards shall continue in full force and effect in accordance with their respective terms and the terms

and conditions of the Company’s 2017 Equity Incentive Plan and 2025 Equity Incentive Plan, as applicable (the “Plans”).

Employee further ratifies and confirms to the Company that the Equity Awards constitute the totality of the equity and debt securities

of the Company and any of the Company’s subsidiaries or affiliates beneficially owned by Employee or to which Employee otherwise

has rights as of the date of this Agreement.

Article

RELEASES AND NON-DISPARAGEMENT

2.1 Release

of Claims. In consideration for the Company’s promises set forth in this Agreement, Employee, on behalf of Employee,

Employee’s heirs, executors, legal representatives, spouse and assigns (the “Employee Releasing Parties”),

hereby fully and forever releases the Company and the Company’s past and present officers, directors, employees, investors, stockholders,

administrators, subsidiaries, affiliates, predecessor and successor corporations, assigns, attorneys and insurers (each a “Company

Released Party”, and collectively, the “Company’s Released Parties”) of and from any claim,

duty, obligation or cause of action relating to any matters of any kind, whether presently known or unknown, suspected or unsuspected,

that any of them may possess arising from any omissions, acts or facts that have occurred through the date that Employee signs this Agreement,

including, without limitation, any and all claims:

(a) which

arise out of, result from, or occurred in connection with Employee’s employment by the Company or any of its affiliated entities,

the termination of that employment relationship, any events occurring in the course of that employment, the Offer Letter, or any events

occurring prior to the execution of this Agreement;

(b) for

discrimination, harassment and/or retaliation; breach of contract, both express and implied; breach of a covenant of good faith and fair

dealing, both express and implied; negligent or intentional infliction of emotional distress; negligent or intentional misrepresentation;

negligent or intentional interference with contract or prospective economic advantage; slander, libel or invasion of privacy; violation

of public policy; fraud, misrepresentation or conspiracy; and false imprisonment;

wrongful discharge of employment, any and all claims for wrongful discharge of employment, and/or (ii) violation of any federal, state

or municipal statute relating to employment or employment discrimination, including, without limitation, (A) Title VII of the Civil

Rights Act of 1964, as amended, (B) the Civil Rights Act of 1866, as amended, (C) the Civil Rights Act of 1991, as amended, (D) the Employee

Retirement and Income Security Act of 1974, as amended, (E) the Age Discrimination in Employment Act of 1967, as amended (the “ADEA”),

including, without limitation, by the Older Workers’ Benefit Protection Act, as amended (“OWBPA”), (F)

the OWBPA, (G) the Americans with Disabilities Act of 1990, as amended, (H) any applicable state Persons with Disabilities Civil Rights

Act, as amended, (I) any applicable state Whistleblowers Protection Act, as amended, (J) Genetic Information Nondiscrimination Act (GINA),

and (K) the Immigration Reform and Control Act (IRCA);

(d) under

Minnesota common law or state statute including, but not limited to, those alleging wrongful discharge, express of implied breach of

contract, negligence, invasion of privacy, intentional infliction of emotional distress, fraud, defamation, or violations of the Minnesota

Human Rights Act (the “MHRA”), the Minnesota Equal Pay for Equal Work Law, the Minnesota healthcare worker

whistleblower protection laws, the Minnesota family leave law; the Minnesota personnel record access statutes, all as amended together

with all of their respective implementing regulations and/or any other federal, state, local or foreign law (statutory, regulatory or

otherwise) that may be legally waived and released;

(e) for

back pay or other unpaid compensation;

(f) relating

to equity of the Company; and/or

(g) for

attorneys’ fees and costs.

the fullest extent permitted by law, Employee will not take any action that is contrary to the covenants and agreements Employee has

made in this Agreement. Employee represents that Employee has not filed any lawsuit, arbitration, or other claim against any of the Company’s

Released Parties. Employee states that Employee knows of no violation of state, federal, or municipal law or regulation by any of the

Company’s Released Parties, and knows of no ongoing or pending investigation, charge, or complaint by any agency charged with enforcement

of state, federal, or municipal law or regulation. While nothing in this Agreement prevents state or federal agencies from enforcing

laws within their jurisdictions, Employee agrees Employee shall not receive any individual monetary damages, recovery and/or relief of

any type related to any released claim(s), whether pursued by Employee or any governmental agency, other person or group; provided that

nothing in the Agreement prevents Employee from participating in the whistleblower program maintained by the SEC and receiving a whistleblower

award thereunder. Employee hereby agrees that the release set forth in this Agreement shall be and remain in effect in all respects as

a complete general release as to the matters released. Notwithstanding anything in this Agreement to the contrary, nothing herein release

any claim for indemnification, contribution, defense or coverage, from or through the Company or its insurers, under the Company’s

(or its affiliates’) charter, By-laws, applicable law, or applicable insurance policies, with respect to prior actions or inactions

relating in any way to Employee’s duties as an employee of the Company. Each Company Released Party is an intended third party

beneficiary of this Agreement and entitled to enforce the release in this Section 2.1 as if such Company Released Party was a

Party to this Agreement.

2.2 Acknowledgment

of Waiver of Claims under ADEA and MHRA. Employee acknowledges that he is waiving and releasing any rights he may have

under the OWBPA, the ADEA, and the MHRA, and that this waiver and release is knowing and voluntary. Employee acknowledges that the

consideration given for this waiver and release is in addition to anything of value to which Employee was already entitled. Employee

further acknowledges that he has been advised by this writing that: (a) he should consult with an attorney of his choice concerning

the terms of this Agreement prior to executing this Agreement; (b) he has at least twenty-one (21) days within which to consider

this Agreement and that if he signs this Agreement before expiration of that review period, he does so knowingly and voluntarily and

with the intent of waiving his right to utilize the full review period; (c) he has the right to revoke his release of claims,

insofar as it extends to potential claims arising under the ADEA, by informing the Company of such revocation within seven (7)

calendar days following his execution of this Agreement; and (d) he has the right to rescind his release of claims, insofar as it

extends to potential claims arising under the MHRA, by informing the Company of such rescission within fifteen (15) calendar days

following Employee’s execution of this Agreement. Employee further understands that these revocation and rescission periods

shall run concurrently, and that this Agreement is not effective until the fifteen (15) day rescission period has expired without

any revocation being communicated. Communication of any such revocation by Employee to the Company shall be provided in writing and

mailed by certified or registered mail with return receipt requested and addressed to the Company at its principal corporate offices

to the attention of the CEO.

2.3 No

Admission of Liability. Neither this Agreement nor any statement contained herein shall be deemed to constitute an admission

of liability on the part of the parties herein released. This Agreement’s execution and implementation may not be used as evidence,

and shall not be admissible in a subsequent proceeding of any kind, except one alleging a breach of this Agreement or the Inventions

Assignment Agreement.

2.4 Non-Disparagement.

To the fullest extent permitted by law, Employee covenants and agrees that Employee shall not make or cause to be made any

statements, observations, opinions or communicate any information (whether in written or oral form) that defame, slander or are likely

in any way to harm the reputation of the Company or any of its subsidiaries, affiliates, directors, or officers or tortiously interfere

with any of the other Company’s business relationships. Any violation of the covenant contained in this Section 2.4 will

result in irreparable damage and the Company shall be entitled to injunctive and other equitable relief.

Article

REPRESENTATIONS

AND WARRANTIES

3.1 Representations

and Warranties of Employee. Employee warrants and represents to the Company that Employee:

(a) has

been advised to consult with legal counsel in entering into this Agreement;

(b) has

entirely read this Agreement;

voluntarily executed this Agreement without any duress or undue influence and with the full intent of releasing all claims;

(d) has

received no promise, inducement or agreement not herein expressed with respect to this Agreement or the terms of this Agreement;

(e) is

the only person (other than Employee’s heirs) who is or may be entitled to receive or share in any damages or compensation on account

of or arising out of Employee’s relationship with, or providing services to, the Company or any of its affiliated entities, the

termination of that relationship or services, any actions taken in the course of that relationship or services, and any events related

to that relationship or services or occurring prior to the execution of this Agreement;

(f) understands

and agrees that in the event any injury, loss, or damage has been sustained by Employee which is not now known or suspected, or in the

event that the losses or damage now known or suspected have present consequences not known or suspected, this Agreement shall nevertheless

constitute a full and final release as to the parties herein released, and that this Agreement shall apply to all such unknown or unsuspected

injuries, losses, damages or consequences; and

(g) expressly

acknowledges that Employee’s entry into this Agreement is in exchange for consideration in addition to anything of value to which

Employee is already entitled.

3.2 Authority.

Employee represents and warrants that Employee has the capacity to act on Employee’s own behalf and on behalf of all who might

claim through Employee to bind them to the terms and conditions of this Agreement. Employee represents and warrants that Employee has

not assigned any claim released under this Agreement, and there are no liens or claims of lien or assignments in law or equity or otherwise

of or against any of the claims or causes of action released herein.

3.3 No

Other Representations. Neither Party has relied upon any representations or statements made by the other Party hereto which

are not specifically set forth in this Agreement.

Article

MISCELLANEOUS

4.1 Severability.

If any provision of this Agreement is held to be unenforceable, then such provision will be construed or revised in a manner so as to

permit its enforceability to the fullest extent permitted by applicable law. If such provision cannot be reformed in that manner, such

provision will be deemed to be severed from this Agreement, but every other provision of this Agreement will remain in full force and

effect.

4.2 Entire

Agreement. This Agreement, together with the Inventions Assignment Agreement and the Consulting Agreement, represents the

entire agreement and understanding between the Company and Employee concerning Employee’s separation from the Company, and supersedes

and replaces any and all prior agreements and understandings concerning Employee’s separation from the Company, including without

limitation the Offer Letter, provided, however, that this Agreement does not supersede or modify any continuing obligations of Employee

under the Inventions Assignment Agreement, which shall continue in full force and effect. This Agreement may only be amended by a writing

signed by Employee and the Company.

4.3 Assignment.

This Agreement may not be assigned by Employee without the prior written consent of the Company. The Company may assign this Agreement

without Employee’s consent in connection with a merger or sale of its assets and/or to a corporation controlling, controlled by

or under common control with the Company. This Agreement shall inure to the benefit of, and be binding upon, each Party’s respective

heirs, legal representatives, successors and assigns.

4.4 Governing

Law; Consent to Jurisdiction, Waiver of Jury Trial. This Agreement shall be governed by and construed in accordance with the

internal laws of the State of Minnesota, without regard to its principles of conflicts of laws. EACH OF THE PARTIES HERETO WAIVES ANY

RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY

AS TO THIS WAIVER. In addition, should it become necessary for the Company to seek to enforce any of the covenants contained in this

Agreement through any legal, administrative or alternative dispute resolution proceeding, Employee shall reimburse the Company for its

reasonable fees and expenses (legal costs, attorneys’ fees and otherwise) related thereto.

4.5 Counterparts/Electronic

Execution and Delivery. This Agreement may be executed in one or more counterparts and by facsimile or by electronic delivery,

each of which shall constitute an original and all of which together shall constitute one and the same instrument. Signatures of the

Parties transmitted by facsimile or via .pdf format shall be deemed to be their original signatures for all purposes. The words “execution,”

“signed,” “signature,” and words of like import shall be deemed to include electronic signatures or the keeping

of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature

or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including

the Federal Electronic Signatures in Global and National Commerce Act, the Minnesota Uniform Electronic Transactions Acts, or any other

similar state laws based on the Uniform Electronic Transactions Act. This Agreement and any signed agreement or instrument entered into

in connection with this Agreement, and any amendments hereto or thereto, to the extent delivered by means of a facsimile machine or electronic

mail (any such delivery, an “Electronic Delivery”), will be treated in all manner and respects as an original

agreement or instrument and will be considered to have the same binding legal effect as if it were the original signed version thereof

delivered in person. At the request of any Party hereto or to any such agreement or instrument, each other Party hereto or thereto will

re-execute original forms thereof and deliver them to all other Parties. No Party hereto or to any such agreement or instrument will

raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted

or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such Party forever waives

any such defense, except to the extent such defense related to lack of authenticity.

Witness Whereof, the Parties have executed and delivered

this Agreement as of the date first written above.

The Company:

EMPLOYEE:

NeuroOne Medical Technologies Corporation

By:

/s/ Dave Rosa

/s/ Ron McClurg

Name:

Dave Rosa

Ron McClurg

Title:

CEO and President

Date: April 28, 2026

Signature

to Update Release Provision:

(To

be signed by Employee on or within 7 days of the Separation Date)

Capitalized

terms used below have the meanings set forth in the foregoing Agreement. In consideration of the promises set forth in the Agreement,

Employee, on behalf of himself and the Employee Releasing Parties, fully and forever releases, acquits, and discharges the Company’s

Released Parties from any liability relating to any claims that may have arisen between his signature date on the preceding signature

page and his signature date below, consistent with his initial release of claims set forth under Section 2.1 of the Agreement.

Employee

acknowledges that he is waiving and releasing any rights he may have under the OWBPA, the ADEA, and the MHRA, and that this waiver and

release is knowing and voluntary. Employee acknowledges that the consideration given for this waiver and release is in addition to anything

of value to which Employee was already entitled. Employee further acknowledges that he has been advised by this writing that: (a) he

should consult with an attorney of his choice concerning the terms of this Agreement prior to executing this Agreement; (b) he has had

more than twenty-one (21) days within which to consider this Agreement; (c) he has the right to revoke his release of claims, insofar

as it extends to potential claims arising under the ADEA, by informing the Company of such revocation within seven (7) calendar days

following his execution of this Agreement; and (d) he has the right to rescind his release of claims, insofar as it extends to potential

claims arising under the MHRA, by informing the Company of such rescission within fifteen (15) calendar days following Employee’s

execution of this Agreement. Employee further understands that these revocation and rescission periods shall run concurrently, and that

this Agreement is not effective until the fifteen (15) day rescission period has expired without any revocation being communicated. Communication

of any such revocation by Employee to the Company shall be provided in writing and mailed by certified or registered mail with return

receipt requested and addressed to the Company at its principal corporate offices to the attention of the CEO.

By:

Date:

, 2026

Ron McClurg

Exhibit

CONSULTING

AGREEMENT

Exhibit A - 1

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Apr. 24, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 24, 2026

Entity File Number

001-40439

Entity Registrant Name

NeuroOne

Medical Technologies Corporation

Entity Central Index Key

0001500198

Entity Tax Identification Number

27-0863354

Entity Incorporation, State or Country Code

Entity Address, Address Line One

7599

Anagram Dr.

Entity Address, City or Town

Eden Prairie

Entity Address, State or Province

Entity Address, Postal Zip Code

55344

City Area Code

952

Local Phone Number

426-1383

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, par value

$0.001 per share

Trading Symbol

NMTC

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration